The DOI matches its Crossref record; 186 of the 187 references it cites were found in a registry or an index, and 1 are not checked yet.
Clinical protein science in translational medicine targeting malignant melanoma
Open accessAbstract
Melanoma of the skin is the sixth most common type of cancer in Europe and accounts for 3.4% of all diagnosed cancers. More alarming is the degree of recurrence that occurs with approximately 20% of patients lethally relapsing following treatment. Malignant melanoma is a highly aggressive skin cancer and metastases rapidly extend to the regional lymph nodes (stage 3) and to distal organs (stage 4). Targeted oncotherapy is one of the standard treatment for progressive stage 4 melanoma, and BRAF inhibitors (e.g. vemurafenib, dabrafenib) combined with MEK inhibitor (e.g. trametinib) can effectively counter BRAFV600E-mutated melanomas. Compared to conventional chemotherapy, targeted BRAFV600E inhibition achieves a significantly higher response rate. After a period of cancer control, however, most responsive patients develop resistance to the therapy and lethal progression. The many underlying factors potentially causing resistance to BRAF inhibitors have been extensively studied. Nevertheless, the remaining unsolved clinical questions necessitate alternative research approaches to address the molecular mechanisms underlying metastatic and treatment-resistant melanoma. In broader terms, proteomics can address clinical questions far beyond the reach of genomics, by measuring, i.e. the relative abundance of protein products, post-translational modifications (PTMs), protein localisation, turnover, protein interactions and protein function. More specifically, proteomic analysis of body fluids and tissues in a given medical and clinical setting can aid in the identification of cancer biomarkers and novel therapeutic targets. Achieving this goal requires the development of a robust and reproducible clinical proteomic platform that encompasses automated biobanking of patient samples, tissue sectioning and histological examination, efficient protein extraction, enzymatic digestion, mass spectrometry-based quantitative protein analysis by label-free or labelling technologies and/or enrichment of peptides with specific PTMs. By combining data from, e.g. phosphoproteomics and acetylomics, the protein expression profiles of different melanoma stages can provide a solid framework for understanding the biology and progression of the disease. When complemented by proteogenomics, customised protein sequence databases generated from patient-specific genomic and transcriptomic data aid in interpreting clinical proteomic biomarker data to provide a deeper and more comprehensive molecular characterisation of cellular functions underlying disease progression. In parallel to a streamlined, patient-centric, clinical proteomic pipeline, mass spectrometry-based imaging can aid in interrogating the spatial distribution of drugs and drug metabolites within tissues at single-cell resolution. These developments are an important advancement in studying drug action and efficacy in vivo and will aid in the development of more effective and safer strategies for the treatment of melanoma. A collaborative effort of gargantuan proportions between academia and healthcare professionals has led to the initiation, establishment and development of a cutting-edge cancer research centre with a specialisation in melanoma and lung cancer. The primary research focus of the European Cancer Moonshot Lund Center is to understand the impact that drugs have on cancer at an individualised and personalised level. Simultaneously, the centre increases awareness of the relentless battle against cancer and attracts global interest in the exceptional research performed at the centre.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, melanoma tumour genomic BRAF driver mutations match corresponding protein sequences97, illustrating that proteomic landscapes add value to genomic data, when considered with patient tumour histopathology and clinical metadata98.”
From A high-stringency blueprint of the human proteome (2020) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Universal sample preparation method for proteome analysis
Wiśniewski, J. R., Zougman, A., Nagaraj, N., & Mann, M. (2009) · Nature Methods · doi:10.1038/nmeth.1322 · Cited by 8,352
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215 · cited 1×
“Recent epidemiological study stated melanoma within the top three cancers with the largest increase in incidence (39% from 2006 to 2016) (Falzone et al. 2018; Fitzmaurice et al. 2018).”
BackgroundThe Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Cited by
Asymmetric organocatalysis: an enabling technology for medicinal chemistry
Han, B., He, X.-H., Liu, Y.-Q., He, G., Peng, C., & Li, J.-L. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00196a · Cited by 402
A high-stringency blueprint of the human proteome
Adhikari, S., Nice, E. C., Deutsch, E. W., Lane, L., Omenn, G. S., Pennington, S. R., Paik, Y.-K., Overall, C. M., Corrales, F. J., Cristea, I. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19045-9 · Cited by 210
Self-citationTowards the overcoming of anticancer drug resistance mediated by p53 mutations
Cao, X., Hou, J., An, Q., Assaraf, Y. G., & Wang, X. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100671 · Cited by 172
Lu, H., Hou, L., Zhang, Y., Guo, T., Wang, Y., & Xing, M. (2023) · Environmental Toxicology · doi:10.1002/tox.24068 · Cited by 106
Digital Barcodes for High-Throughput Screening
Yang, Z. R., Chen, J., Xiao, Y., Yang, C., Zhao, C., Chen, D., & Weitz, D. A. (2024) · Chem & Bio Engineering · doi:10.1021/cbe.3c00085 · Cited by 43
Metadata
- Authors
- Gil, J., Betancourt, L. H., Pla, I., Sanchez, A., Appelqvist, R., Miliotis, T., Kuras, M., Oskolas, H., Kim, Y., Horvath, Z., Eriksson, J., Berge, E., Burestedt, E., Jönsson, G., Baldetorp, B., Ingvar, C., Olsson, H., Lundgren, L., Horvatovich, P., Murillo, J. R., Sugihara, Y., Welinder, C., Wieslander, E., Lee, B., Lindberg, H., Pawłowski, K., Kwon, H. J., Doma, V., Timar, J., Karpati, S., Szasz, A. M., Németh, I. B., Nishimura, T., Corthals, G., Rezeli, M., Knudsen, B., Malm, J., & Marko-Varga, G.
- Affiliations
- Lund University (SE)
- University of Groningen (NL)
- Warsaw University of Life Sciences (PL)
- Semmelweis University (HU)
- University of Szeged (HU)
- Tokyo Medical University (JP)
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Gil, Jeovanis
- Betancourt, Lazaro Hiram
- ORCID
- Gil, Jeovanis
- Betancourt, Lazaro Hiram
- Appelqvist, Roger
- Miliotis, Tasso
- Kuras, Magdalena
- Kim, Yonghyo
- Eriksson, Jonatan
- Ingvar, Christian
- Horvatovich, Peter
- Murillo, Jimmy Rodriguez
- Sugihara, Yutaka
- Welinder, Charlotte
- Lee, Boram
- Pawłowski, Krzysztof
- Kwon, Ho Jeong
- Németh, István Balázs
- Nishimura, Toshihide
- Corthals, Garry
- Rezeli, Melinda
- Knudsen, Beatrice
- Malm, Johan
- Venue
- Cell Biology and Toxicology
- Published
- 2019-03-21
- Volume
- 35
- Issue
- 4
- Pages
- 293-332
- ISSN
- 0742-2091 (ISSN-L)
- 1573-6822
- PMC
- PMC6757020
- OpenAlex
- W2925257594
- Cited by
- 45
- References
- 187
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 1 · 2022: 6 · 2021: 14 · 2020: 8 · 2019: 5
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Cell Biology and Toxicology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
- Lund University Publications (Lund University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Fru Berta Kamprads Stiftelse
- National Research Foundation of Korea (2015K1A1A2028365, 2016K2A9A1A03904900)
- NIH/NCI International Cancer Proteogenome Consortium (MOU NIH-LUND 2017-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- melanoma, clinical proteomics, proteogenomics, BRAF V600E mutation, vemurafenib, dabrafenib, trametinib, drug resistance, tumor markers, therapeutic target, phosphoproteomics, mass spectrometry imaging, metastatic melanoma, post-translational modification
- MeSH terms
- Melanoma, Cutaneous Malignant, Cutaneous Malignant Melanoma, Humans, Imidazoles, Melanoma, Neoplasm Staging, Oximes, Pyridones, Pyrimidinones, Skin Neoplasms, Biomarkers, Tumor, Biological Specimen Banks, Drug Resistance, Neoplasm, Proteomics, Protein Kinase Inhibitors, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical protein science in translational medicine targeting malignant melanoma. https://app.cochat.ai/papers/10.1007/s10565-019-09468-6
- The paper
- Gil, J., Betancourt, L. H., Pla, I., Sanchez, A., Appelqvist, R., Miliotis, T., Kuras, M., Oskolas, H., Kim, Y., Horvath, Z., Eriksson, J., Berge, E., Burestedt, E., Jönsson, G., Baldetorp, B., Ingvar, C., Olsson, H., Lundgren, L., Horvatovich, P., . . . Marko-Varga, G. (2019). Clinical protein science in translational medicine targeting malignant melanoma. Cell Biology and Toxicology. https://doi.org/10.1007/s10565-019-09468-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.